浩鼎啟動OBI-992一/二期臨床試驗
June 12, 2024 05:55 ET
|
OBI Pharma Inc.
OBI-992以TROP2為標靶的ADC 研究目的在評估治療多種實體腫瘤的安全性和有效性 台灣台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎 (4174.TWO)今（12）日宣布，正式啟動OBI-992的人體一/二期臨床試驗。OBI-992係浩鼎自行研發，以TROP2為標靶所設計的抗體藥物複合體(antibody-drug conjugate,...
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
June 11, 2024 15:30 ET
|
Tevogen Bio Inc
Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
June 11, 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids
June 11, 2024 07:05 ET
|
Kraig Biocraft Laboratories
Kraig Labs’ (OTCQB: KBLB) BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness.
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 06:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 01:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia
June 06, 2024 21:13 ET
|
EnGeneIC
SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has...
Rapport Therapeutics Announces Pricing of Initial Public Offering
June 06, 2024 18:54 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
BioNTX Announces 10th Annual iC³® Life Science & Healthcare Innovation Summit
June 06, 2024 10:00 ET
|
Bio North Texas
BioNTX, the leading biotechnology trade organization in North Texas, is thrilled to announce the 10th Annual iC³® Life Science Summit.
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
June 06, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data...